Individualising Antithrombotic Strategies for Established Coronary Artery Disease

Published: 07 March 2023

  • Views:

    Views Icon 11670
  • Likes:

    Heart Icon 7
  • episode_image
    Now Playing
    Part 2
    Summary
    Marco Valgimigli
    Up Next
Average (ratings)
No ratings
Your rating

Overview

This three-part programme delves into the critical importance of individualised antithrombotic treatment in both Acute Coronary Syndrome (ACS) and Chronic Coronary Syndrome (CCS).

 

Part one of this programme presents two compelling patient case studies. Prof Pascal Vranckx (Hartcentrum Hasselt, BE) presents a complex 62-year old male with stable angina and HFrEF, undergoing an elective angiography and Prof Eliano Navarese (Nicolaus Copernicus University, PL) presents a 62-year-old male with persistent chest pain, transferred for PCI within 24 hours of onset. 

 

In part two, during a roundtable chaired by Prof Marco Valgimigli (Instituto Cardiocentro Ticino, Lugano, CH), our panel of experts review the two intriguing patient cases, providing valuable insights into the challenges faced and highlighting the need for tailored treatment approaches. This roundtable brings to the forefront impactful new trial data that will reshape the way we approach antithrombotic therapies in ACS and CCS.

 

The panel, including Prof Vijay Kunadian (Newcastle University, UK), discuss practical solutions to common challenges experienced in real-world practice whilst summarising the new recommendations for antithrombotic treatment strategies in ACS and CCS patients with established coronary artery disease (CAD) made in the 2022 joint clinical consensus statement of the European Association of Percutaneous Coronary Intervention (EAPCI), Association for Acute Cardiovascular Care (ACVC) and European Association of Preventive Cardiology (EAPC).

 

In the final part, we offer a short but impactful follow-up on the patient journey. 

 

Please note that the live version of this roundtable was CME accredited; this on-demand version is not. 
 

This programme is supported by an unrestricted educational grant from AstraZeneca.

Learning Objectives

  • Summarise current guidance for choosing antithrombotic therapy in established CAD
  • Describe current gaps in clinical evidence and what is missing from current guidance
  • Adopt an evidence-based approach for managing patients with ACS and CCS

Target Audience

  • General Cardiologists
  • Interventional Cardiologists
  • Nurses
  • HCPs

More from this programme

Part 1

Patient Follow Up

In the final part of this programme, we revisit Prof Vranckx to hear his patient's one year follow up journey. 

Part 2

Roundtable Summary

Prof Valgimigli provides an overview and summary of the following roundtable in this short and concise video.

1 session
Summary Watch now

Part 3

Patient Cases Revisited

Prof Navarese and Prof Vranckx present the two clinical case studies on ACS and CCS to be examined in this programme. Additionally, the panel review audience poll results on the initial approach to these patients.

Part 4

Development of a Consensus for Antithrombotic Therapy in CAD

Here Prof Valgimigli discusses the rationale behind the development of the new consensus statements on ACS and CCS, presents key data that has driven the recommendations, and highlights the shift in antiplatelet paradigm the consensus brings.

Part 5

Antithrombotic Treatment Strategies in Patients With Established CAD: Results of Two Network Meta-Analyses

Prof Navarese presents the results of a companion network meta-analysis on antithrombotic strategies in established CAD, including a ranking of individual strategies to identify best-in-class agents for key primary and secondary endpoints.

Part 6

Clinical Consensus Statements on Patients With ACS

Prof Kunadian summarises the recommendations made in the new joint clinical consensus statement of the EAPCI, ACVC and EAPC on patients with ACS, covering short and long-term strategy for monotherapy and dual/triple antiplatelet therapy.

Part 7

Clinical Consensus Statements on Patients With CCS

Prof Vranckx summarises the recommendations made in the new joint clinical consensus statement of the EAPCI, ACVC and EAPC on patients with CCS, covering individualised antithrombotic approaches and examination of bleeding risk.

Part 8

Panel Discussion and Q&A

Chaired by Prof Valgimigli, the faculty join to discuss the key learning points of the broadcast, answer audience questions and provide their expert opinion on the exemplar case studies.

Part 9

Patient Case Studies

If you missed the first part of the programme, you can catch up here. In these short videos, Prof Vranckx and Prof Navarese present compelling patient case studies.

Faculty Biographies

Marco Valgimigli

Marco Valgimigli

Deputy Chief of Cardiology

Prof Marco Valgimigli is an Interventional Cardiologist and Deputy Chief of Cardiology at the Cardiocentro Ticino Institute in Lugano, Switzerland.

He obtained his medical degree from the University of Bologna, and completed his training in internal medicine at the same university. He received a degree in cardiological sciences at the University of Ferrara and a PhD in interventional cardiology at Erasmus Medical Center in Rotterdam.

Prof Valgimigli’s areas of research are wide ranging and include high-risk percutaneous interventions (PCI); invasive treatment of myocardial ischaemia (MI); reparative medicine with adult stem cells during MI and heart failure; antithrombotic therapy during and after PCI; and prognostic stratification during acute coronary syndromes and MI.

View full profile